Bone destruction through the activation of osteoclasts could trigger the release of tumor growth factors [85], while the blockade of CCL2 with specific shRNA or neutralizing antibodies could significantly impair bone resorption and prostate cancer-induced formation of osteoclasts [86]. This evidence concerns the gene CCL2 and prostate carcinoma.